LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

Strona główna・Stock List・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Open

SectorHealthcare

21.38 1.33

Buy Sell

Overview

Share price change

24h

Current

Min

21.15

Max

22.04

Key metrics
By Trading Economics
Income	-29M -11M
Sales	-24M 105M
EPS	-0.09
Profit margin	-10.717
Employees	354
EBITDA	-31M -8.5M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+66.01% upside

Dividends
By Dow Jones
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	-329M 2.6B
Previous open	20.05
Previous close	21.38

News Sentiment

By Acuity

46%

54%

140 / 344 Ranking in Healthcare

Arcutis Biotherapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 maj 2026, 16:52 UTC

Major News Events

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 maj 2026, 23:57 UTC

Earnings

Sociedad Quimica 1Q Rev $1.76B >SQM

26 maj 2026, 23:57 UTC

Earnings

Sociedad Quimica 1Q EPS $1.28 >SQM

26 maj 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 maj 2026, 21:54 UTC

Earnings

Webco Industries 3Q EPS $11.61 >WEBC

26 maj 2026, 21:54 UTC

Earnings

Webco Industries 3Q Sales $179.6M >WEBC

26 maj 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 maj 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26 maj 2026, 20:58 UTC

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 maj 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 maj 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26 maj 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 maj 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 maj 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 maj 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 maj 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26 maj 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 maj 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26 maj 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 maj 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 maj 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 maj 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 maj 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 maj 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26 maj 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

26 maj 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 maj 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 maj 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Peer Comparison

Price change

Arcutis Biotherapeutics Inc Forecast

Price Target

By TipRanks

66.01% upside

12 Months Forecast

Average 34.63 USD 66.01%

High 36 USD

Low 33 USD

Based on 8 Wall Street analysts offering 12 month price targets forArcutis Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Arcutis Biotherapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

140 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.